Peptides / Compound guide

GHRP-2 guide

GHRP-2, also called pralmorelin, is a synthetic growth hormone-releasing peptide studied in human endocrine research.[4][2][1] The library's half-life reference comes from human intravenous research, while PinPoint models a subcutaneous recording route.

Editorial still life for peptides research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

Regulatory status
Pralmorelin (GHRP-2) is approved in Japan as a diagnostic agent for endocrine function testing, not as a treatment; FDA lists GHRP-2 for injectable and nasal use in category 2 of its 503B compounding interim policy (bulk substances that may present significant safety risks), noting reports of serious adverse events including death of critically ill study subjects, infection and pancreatitis, though causality has not been established.[4][5]
Half-life
0.55 hours, the terminal half-life after a single intravenous dose in ten prepubertal children in the cited study.[1]
Route
Intravenous (single dose, children) and subcutaneous (daily for five days, healthy young men) in the cited studies.[1][2]
Category
Peptides
Vial size
Not listed

The GHRP-2 half-life came from an intravenous study in prepubertal children, while the app records a subcutaneous route. That population-and-route distinction stays beside the 0.55-hour number.[1]

What the research says

The first cited study characterized GHRP-2 in ten prepubertal children with short stature after a single intravenous administration. Repeated blood samples measured both the peptide and growth hormone. Pharmacokinetic models were fitted to GHRP-2 and growth hormone levels, and a linked pharmacokinetic-pharmacodynamic model related GHRP-2 levels to the growth hormone response.[1]

The peptide's terminal half-life was 0.55 hours on average, while growth hormone had its own timing parameters. The small pediatric population and intravenous route qualify this estimate. The authors wrote that the results would allow later studies of non-intravenous dosing in children; the study itself gave only intravenous doses.[1]

A second study gave subcutaneous GHRP-2 to nine healthy young men over five days. Researchers measured growth hormone, IGF-I, binding protein, and osteocalcin. Growth hormone responses attenuated during repeated exposure, while mean IGF-I did not increase and osteocalcin rose. This provides separate adult response context, not a replacement for the pediatric intravenous disposition data.[2]

Amounts

No verified product total exists for GHRP-2, so no vial size or preparation calculation is presented here.

This guide lists no human dose figure for GHRP-2.

Open the calculator for amount conversions

Half-life and timing

0.55 hours, the terminal half-life after a single intravenous dose in ten prepubertal children in the cited study.[1]

The stored 0.55 hours equal 33 minutes. At 66 minutes the mathematical amount is one quarter of its starting value; at 165 minutes it is one thirty-second. These positions are derived from the pediatric intravenous reference scalar. They do not measure adult subcutaneous absorption, whose bioavailability and peak time are not stated by that source. The chart contains no added dose events. Its short endpoint explains the model's arithmetic without prescribing an interval or resolving the route extrapolation.

GHRP-2: modeled fraction over five half-livesStarting at 100 percent, the model halves each 0.55 hours. After 2.75 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%0.55 h50%1.1 h25%1.65 h12.5%2.2 h6.25%2.75 h3.125% Continue to the calculator

Reconstitution

No numerical reconstitution example is supplied because the original vial-size input is unverified. Concentration arithmetic requires an independently established compound amount and final liquid volume; the half-life reference supplies neither. A historical library value cannot substitute for a checked product document. The calculator link remains available as a general unit-conversion tool, while this guide leaves the missing external input unresolved instead of presenting a plausible quantity as verified.

No verified vial example
Open GHRP-2 conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Track vials and prefilled pens side by side.[6]

The Home curve models your levels between doses from an estimate built on the half-life value stored for each compound, published where a published value exists and an estimate where none does. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

Does the GHRP-2 half-life come from subcutaneous research?
The library identifies a single-dose intravenous study in prepubertal children as the half-life source. Its 0.55-hour value is carried into a subcutaneous tracking model with explicit extrapolation. The cited study does not supply subcutaneous bioavailability or absorption timing.[1]
Does the GHRP-2 study supply subcutaneous absorption parameters?
The library says the cited intravenous study does not state subcutaneous bioavailability or time to peak. Those fields are authored tracking estimates. A separate publication mentioning subcutaneous schedules cannot automatically provide the missing measured parameters.[1][3]
Why retain the pediatric population when reporting GHRP-2's half-life?
It identifies who supplied the reference observations. Removing it could make the number look like a measured adult subcutaneous value. The guide preserves both population and route so the 33-minute conversion does not conceal the extrapolation.[1]

Sources

Sources checked against the cited documents on 19 November 2026.

  1. Pharmacokinetics and pharmacodynamics of GHRP-2, phase I study in children, 1998 (PubMed 9543135)Abstract read 19 November 2026: ten prepubertal children, single 1 microgram/kg intravenous dose.Retrieved 2026-11-19 · human-study
  2. Five days of subcutaneous GHRP-2 in healthy young men, 1998 (PubMed 9820615)Abstract read 19 November 2026: nine healthy subjects, daily subcutaneous injection over 5 days.Retrieved 2026-11-19 · human-study
  3. Retrospective chart review, 14 men, GHRP-2 with GHRP-6 and sermorelin (PMC5675260)A retrospective review of medical records; GHRP-2 only in combination; no pharmacokinetics.Retrieved 2026-11-19 · human-study
  4. KEGG DRUG D02040, pralmorelinPralmorelin dihydrochloride (USAN); listed among new drug approvals in Japan, efficacy: diagnostic (endocrine function).Retrieved 2026-11-19 · regulator-database
  5. FDA, certain bulk drug substances for use in compounding that may present significant safety risksContent current as of 22 April 2026; read on 19 November 2026.Retrieved 2026-11-19 · regulator
  6. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description